| Amie Lynn Fannin, APRN | |
|
613 23rd St Ste 430, Ashland, KY 41101-2885 | |
| (606) 408-8200 | |
| (606) 408-6291 |
| Full Name | Amie Lynn Fannin |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 3 Years |
| Location | 613 23rd St Ste 430, Ashland, Kentucky |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467635391 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 3016180 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| King's Daughters' Medical Center | Ashland, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kings Daughters Medical Specialties Inc | 6103968029 | 328 |
| W. Michael Spurlock, D.c., P.s.c. | 8527115260 | 7 |
News Archive
Efforts to protect the tumor-suppressor p53 could just as easily shelter a mutant version of the protein, causing cancer cells to thrive and spread rather than die, according to research by scientists at The University of Texas M. D. Anderson Cancer Center reported in the current issue of the journal Genes and Development.
Medicity, Inc. today announced that IASIS Healthcare went live with the Medicity Novo Grid solution in two (Florida and Utah) of its six regions. The solution enables IASIS to exchange health information electronically with providers connected on the Grid – whether the providers use an electronic health record (EHR) or operate a paper-based practice.
Globally every year, obese people waste billions of pounds on food products that 'imply' that they aid weight loss, but are totally ineffective, says a nutritional expert on bmj.com.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated patient enrollment in an open-label, multi-center Phase 1b clinical trial evaluating tivozanib in combination with oral capecitabine (Xeloda®) in patients with certain advanced solid tumors.
DestinationRx, a leading provider of Medicare plan and drug comparison tools, today announced the results of a DestinationRx analysis showing a significant increase in consumers choosing to enroll in health plans online, coupled with a parallel decrease in call center enrollments. An analysis of DestinationRx commercial enrollments shows a 12 percent shift from call center to online enrollment for 2008 to 2009 and an 11 percent shift from 2009 to 2010, for a 23 percent total increase in online enrollments over just two years.
› Verified 7 days ago
| Entity Name | W. Michael Spurlock, D.c., P.s.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336280379 PECOS PAC ID: 8527115260 Enrollment ID: O20090415000047 |
News Archive
Efforts to protect the tumor-suppressor p53 could just as easily shelter a mutant version of the protein, causing cancer cells to thrive and spread rather than die, according to research by scientists at The University of Texas M. D. Anderson Cancer Center reported in the current issue of the journal Genes and Development.
Medicity, Inc. today announced that IASIS Healthcare went live with the Medicity Novo Grid solution in two (Florida and Utah) of its six regions. The solution enables IASIS to exchange health information electronically with providers connected on the Grid – whether the providers use an electronic health record (EHR) or operate a paper-based practice.
Globally every year, obese people waste billions of pounds on food products that 'imply' that they aid weight loss, but are totally ineffective, says a nutritional expert on bmj.com.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated patient enrollment in an open-label, multi-center Phase 1b clinical trial evaluating tivozanib in combination with oral capecitabine (Xeloda®) in patients with certain advanced solid tumors.
DestinationRx, a leading provider of Medicare plan and drug comparison tools, today announced the results of a DestinationRx analysis showing a significant increase in consumers choosing to enroll in health plans online, coupled with a parallel decrease in call center enrollments. An analysis of DestinationRx commercial enrollments shows a 12 percent shift from call center to online enrollment for 2008 to 2009 and an 11 percent shift from 2009 to 2010, for a 23 percent total increase in online enrollments over just two years.
› Verified 7 days ago
| Entity Name | Kings Daughters Medical Specialties Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710215736 PECOS PAC ID: 6103968029 Enrollment ID: O20100217000538 |
News Archive
Efforts to protect the tumor-suppressor p53 could just as easily shelter a mutant version of the protein, causing cancer cells to thrive and spread rather than die, according to research by scientists at The University of Texas M. D. Anderson Cancer Center reported in the current issue of the journal Genes and Development.
Medicity, Inc. today announced that IASIS Healthcare went live with the Medicity Novo Grid solution in two (Florida and Utah) of its six regions. The solution enables IASIS to exchange health information electronically with providers connected on the Grid – whether the providers use an electronic health record (EHR) or operate a paper-based practice.
Globally every year, obese people waste billions of pounds on food products that 'imply' that they aid weight loss, but are totally ineffective, says a nutritional expert on bmj.com.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated patient enrollment in an open-label, multi-center Phase 1b clinical trial evaluating tivozanib in combination with oral capecitabine (Xeloda®) in patients with certain advanced solid tumors.
DestinationRx, a leading provider of Medicare plan and drug comparison tools, today announced the results of a DestinationRx analysis showing a significant increase in consumers choosing to enroll in health plans online, coupled with a parallel decrease in call center enrollments. An analysis of DestinationRx commercial enrollments shows a 12 percent shift from call center to online enrollment for 2008 to 2009 and an 11 percent shift from 2009 to 2010, for a 23 percent total increase in online enrollments over just two years.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amie Lynn Fannin, APRN 247 Beacon Hill Rd, Morehead, KY 40351-6030 Ph: (606) 784-1115 | Amie Lynn Fannin, APRN 613 23rd St Ste 430, Ashland, KY 41101-2885 Ph: (606) 408-8200 |
News Archive
Efforts to protect the tumor-suppressor p53 could just as easily shelter a mutant version of the protein, causing cancer cells to thrive and spread rather than die, according to research by scientists at The University of Texas M. D. Anderson Cancer Center reported in the current issue of the journal Genes and Development.
Medicity, Inc. today announced that IASIS Healthcare went live with the Medicity Novo Grid solution in two (Florida and Utah) of its six regions. The solution enables IASIS to exchange health information electronically with providers connected on the Grid – whether the providers use an electronic health record (EHR) or operate a paper-based practice.
Globally every year, obese people waste billions of pounds on food products that 'imply' that they aid weight loss, but are totally ineffective, says a nutritional expert on bmj.com.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated patient enrollment in an open-label, multi-center Phase 1b clinical trial evaluating tivozanib in combination with oral capecitabine (Xeloda®) in patients with certain advanced solid tumors.
DestinationRx, a leading provider of Medicare plan and drug comparison tools, today announced the results of a DestinationRx analysis showing a significant increase in consumers choosing to enroll in health plans online, coupled with a parallel decrease in call center enrollments. An analysis of DestinationRx commercial enrollments shows a 12 percent shift from call center to online enrollment for 2008 to 2009 and an 11 percent shift from 2009 to 2010, for a 23 percent total increase in online enrollments over just two years.
› Verified 7 days ago
Lisa Ellen Spencer, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 613 23rd St Ste 230, Ashland, KY 41101 Phone: 606-324-4745 Fax: 606-324-4941 | |
Tomie Thompson, ARNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1000 Ashland Dr, Ste G1, Ashland, KY 41101 Phone: 606-833-4043 | |
Susan Aliff, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 613 23rd St Ste 520, Ashland, KY 41101 Phone: 606-393-0190 | |
Tracy Ricewick, AGNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 613 23rd St Ste 130, Ashland, KY 41101 Phone: 606-329-9335 | |
Rita Nicole Fletcher, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 399 Diederich Blvd, Ashland, KY 41101 Phone: 606-324-8060 Fax: 606-325-6889 | |
Darren Barker, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 613 23rd St Ste 440, Ashland, KY 41101 Phone: 606-329-2888 | |
Martina Renate Myers, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2201 Lexington Ave, Ashland, KY 41101 Phone: 606-408-4000 Fax: 606-408-6825 |